Two BRAF V600E selective inhibitors vemurafenib (clinical Cmax 127 μM) and dabrafenib (clinical Cmax 4.86 μM) were tested in combination with ipatasertib in two BRAF V600E mutant colon carcinoma lines, 616215-338-R-J1 and 817829-284-R-J1, and in a single BRAF V600E mutant melanoma line, MALME-3M. This evidence concerns the gene BRAF and melanoma.